Use of pneumococcal vaccine

IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines

“…35 Pnc type 3 is a good, type 19F an intermediate, and type 6B a poor immunogen. 42 Possibly Pnc type 3 induced response in immunologically more immature recipients than did types 6B and 19F, and the IgG subclass pattern in the anti-Pnc 3 response resembled that of infants with IgG1 predominance. Only Hammarström et al 18 have previously studied the IgG subclass response to the Pnc PS vaccine in a few adult BMT recipients.…”

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

“…Considering that 40% on average of CAP requiring hospitalization are caused by S. pneumoniae, 2 we estimated an incidence rate of hospitalized pneumococcal pneumonia of 460 cases per 100,000. To determine the incidence of NBPP in general, we used also the fact that 80% of pneumococcal pneumonia are NBPP (BPp = ¼ NBPP), 2 and we used the hospitalization rates defined above (18.6% of NBPP + 95.5% of ¼ NBPp = 460 cases). We obtained 1,083 of NBPP cases per 100,000.…”

“…1 Although, pneumococcal disease can affect all age groups, the elderly and immunocompromised are at highest risk from infection. 2 Moreover, since the introduction of pneumococcal conjugate vaccination in children in 2000, the epidemiology of invasive pneumococcal disease (IPD) has changed with the reported burden of IPD now highest in the elderly population. In the US, the annual incidence of IPD in those ≥65 years of age was recently Vaccination of adults aged 60 years and older against Streptococcus pneumonia is not recommended in Brazil.…”

Outbreak of Pneumococcal Pneumonia among Military Recruits

“…Population based studies carried out in different parts of the world [3], show that the overall rate of invasive pneumococcal disease, is about 15 per 100,000 persons per year. In certain populations and ethnic groups [4,5], the incidence may be increased 10 fold.…”

“…This needs further evaluation. Vaccines have been recommended for prophylaxis [1,3,6]. However, because of differences in serotype prevalence, the vaccine may have lower efficacy in developing countries [6].…”